China Securities Co.,Ltd.: Policy encouragement + new technology promotion + overseas opportunities create new chances, maintaining a bullish outlook on the Innovative Drugs industry.

National policies encourage the development of Innovative Drugs, new technologies promote the rapid growth of the Industry, new opportunities arise for going overseas, and there is a continuous Bullish outlook for the Innovative Drugs Industry.

Zhitong Finance18:54 ET

Shandong Xinhua Pharmaceutical Secures Approval for Drug Marketing Authorization Transfer

TipRanksJan 20 04:10 ET

SHANDONG XINHUA (00719.HK): The hydrochloride levalbuterol nebulization solution has been approved.

On January 20, Gelonghui reported that SHANDONG XINHUA (00719.HK) announced that recently Shandong Xinhua Pharmaceutical received the approved notification for the supplementary application of the hydrochloride levalbuterol nebulization solution issued by the National Medical Products Administration, and the application for the transfer of the marketing authorization holder for this product has been approved. The hydrochloride levalbuterol nebulization solution was approved by the National Medical Products Administration in January 2025, and Shandong Xinhua Pharmaceutical became the marketing authorization holder for this product. The launch of this product is beneficial for enriching the company's respiratory drug product line and enhancing the company's overall competitive advantage.

Gelonghui FinanceJan 20 04:00 ET

Express News | Shandong Xinhua Pharmaceutical- Approval of Supplementary Application Concerning Nebuliser Solution Drugs From Nmpa

ReutersJan 20 03:59 ET

WuXi AppTec leads the surge of Hong Kong stock pharmaceutical shares, while Global Biomedical investment and financing shows signs of recovery.

① The WuXi AppTec system leads the rise of Hong Kong pharmaceutical stocks, which Bullish factors are worth paying attention to? ② Global Biomedical investment and financing has seen some recovery, how do Institutions view it?

cls.cnJan 20 03:30 ET

Sinolink: The policy inflection point is clear, suggesting to start increasing allocation in the pharmaceutical sector.

In the segmented Industry, it is recommended to focus on allocating resources to Innovative Drugs and left-side Sectors (such as Medical Device, Traditional Chinese Medicine, Consumer Medical, chain pharmacies, etc.) for opportunities in reverse situations of individual stocks as the two main lines.

Zhitong FinanceJan 20 00:51 ET